Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods.

DC-SIGN antagonists were designed combining one selective monovalent glycomimetic ligand with trivalent dendrons separated by a rigid core of controlled length. The design combines multiple multivalency effects to achieve inhibitors of HIV infection, which are active in nanomolar concentration.